Intervention

GFF MDI (PT003)

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting0

Common conditions3

Lead sponsors shown1

Clinical trials

6 shown

Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPDNCT02685293 · 2016-12-09

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®NCT03262012 · 2016-08-09

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPDNCT02343458 · 2015-03-30

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDINCT02347085 · 2015-02-01

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and PlaceboNCT02347072 · 2015-02-01

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)NCT01854658 · 2013-07-01

Common conditions

COPD4 Chronic Obstructive Pulmonary Disease1 Chronic Obstructive Pulmonary Disease (COPD)1

Leading sponsors

Pearl Therapeutics, Inc.6

Trial status mix

COMPLETED5

TERMINATED1

Phase mix

PHASE36

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.